- Home
- BEAM vs NOG Comparison
BEAM vs NOG Comparison
Compare BEAM & NOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- NOG
- Stock Information
- Founded
- BEAM 2017
- NOG 2006
- Country
- BEAM United States
- NOG United States
- Employees
- BEAM N/A
- NOG N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- NOG Oil & Gas Production
- Sector
- BEAM Health Care
- NOG Energy
- Exchange
- BEAM Nasdaq
- NOG Nasdaq
- Market Cap
- BEAM 2.3B
- NOG 2.1B
- IPO Year
- BEAM 2020
- NOG N/A
- Fundamental
- Price
- BEAM $25.14
- NOG $22.18
- Analyst Decision
- BEAM Strong Buy
- NOG Buy
- Analyst Count
- BEAM 12
- NOG 8
- Target Price
- BEAM $48.09
- NOG $29.57
- AVG Volume (30 Days)
- BEAM 2.3M
- NOG 2.2M
- Earning Date
- BEAM 11-04-2025
- NOG 11-06-2025
- Dividend Yield
- BEAM N/A
- NOG 8.14%
- EPS Growth
- BEAM N/A
- NOG N/A
- EPS
- BEAM N/A
- NOG 1.82
- Revenue
- BEAM $55,701,000.00
- NOG $2,050,402,000.00
- Revenue This Year
- BEAM N/A
- NOG $18.41
- Revenue Next Year
- BEAM $19.01
- NOG N/A
- P/E Ratio
- BEAM N/A
- NOG $12.16
- Revenue Growth
- BEAM N/A
- NOG 2.50
- 52 Week Low
- BEAM $13.53
- NOG $19.88
- 52 Week High
- BEAM $35.25
- NOG $44.31
- Technical
- Relative Strength Index (RSI)
- BEAM 58.18
- NOG 50.45
- Support Level
- BEAM $20.23
- NOG $20.87
- Resistance Level
- BEAM $22.72
- NOG $22.47
- Average True Range (ATR)
- BEAM 1.68
- NOG 0.85
- MACD
- BEAM 0.36
- NOG 0.10
- Stochastic Oscillator
- BEAM 97.41
- NOG 66.67
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About NOG Northern Oil and Gas Inc.
Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. The company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), the Uinta Basin, and the Appalachian Basin (Pennsylvania and Ohio).